Human MAdCAM-1 antibodies as targeted immune modulators.

Area of Science:

• Immunology
• Gastroenterology
• Biotechnology

Background:

• Inflammatory bowel disease (IBD) involves chronic gastrointestinal inflammation, significantly impacting patient quality of life.
• Mucosal Addressin-Cell Adhesion Molecule 1 (MAdCAM-1) is a key adhesion molecule in the gut vasculature, making it a potential therapeutic target for IBD.

Purpose of the Study:

• To characterize novel monoclonal antibodies (mAbs) targeting human MAdCAM-1 for potential IBD therapeutics.
• To evaluate the efficacy of these mAbs in blocking MAdCAM-1-mediated T cell costimulation.

Main Methods:

• Hybridoma technology was used to generate eight anti-MAdCAM-1 mAb clones.
• Antibody binding affinity was assessed using dissociation constants.
• Immunohistochemistry was employed to detect MAdCAM-1 expression in human small intestinal tissue.
• In vitro assays measured the ability of mAbs to block MAdCAM-1 costimulation of primary human CD4+ T cells.

Main Results:

• Eight mAb clones demonstrated low to sub-nanomolar binding affinities to human MAdCAM-1.
• Only four of the eight mAbs successfully detected MAdCAM-1 in human small intestinal tissue via immunohistochemistry.
• These four clones (1B10, 11C3, 7A2, and 2F3) acted as potent antagonists, inhibiting MAdCAM-1 costimulation of CD4+ T cells.

Conclusions:

• Four specific anti-MAdCAM-1 antibodies show promise as targeted therapeutics for IBD.
• These antibodies can block crucial inflammatory pathways in the gut, potentially alleviating IBD symptoms.